Skip to main content
. 2023 Feb 23;15(3):739. doi: 10.3390/pharmaceutics15030739

Figure 4.

Figure 4

Brain-specific biodistribution of TXB4 and pharmacodynamic activity of TXB4 fused to NT. Mice were dosed with TXB4 or negative isotype control (neg. cont.) at 25 nmol/kg and blood and various organs were collected 18 h after cardiac perfusion. (a) Organ concentrations were measured via ELISA and were presented as fold increase over negative control (mean ± SD, n = 2). (b) Brain and plasma concentrations were assessed via ELISA (mean ± SD, n = 3) and significance was determined via two-tailed, unpaired t-test with * p < 0.05, *** p < 0.0002. (c) The TXB4-NT fusion or NT fused to the Fc domain alone (hFc-NT) were administered to mice at 25 nmol/kg and body temperature was continuously monitored for 24 h. Data presented as a change (Δ) from the pre-dose body temperature measured 15 min before dosing (mean ± SD, n = 4.). Significance was determined via two-way ANOVA and Dunnett’s comparison with * p < 0.05, *** p < 0.0002 and **** p < 0.0001.